AKT1 and melanoma: In the present study, we tested the therapeutic potential of dually targeting the MAPK and PI3K/Akt pathways in melanoma cells for synergistic/additive cell inhibition coupled with thyroid iodide-handling gene expression and radioiodide uptake as a novel therapeutic strategy for melanoma.